Therefore, since the expression of GLUT1 and GLUT8 increases during tumor progression and development of endometrial tumors, these GLUTs could be used as potential biomarkers for prognosis and clinical follow-up of endometrial cancer patients. This evidence concerns the gene SLC2A1 and endometrium neoplasm.